Find drug coverage information and forms for rituximab, by funding source. Includes these indications:
- GPA (granulomatosis with polyangiitis)
- MPA (microscopic polyangiitis)
- Nephrotic syndrome related to GN conditions (e.g., membranous nephropathy)
Pharmaceutical manufacturers offer patient support programs for each of the rituximab medications approved in Canada. These programs offer a range of services including financial assistance, infusion support, and drug access navigation.
Rituximab for GPA or MPA
Rituximab for Nephrotic Syndrome
Disclaimer: The information contained herein (“Information”) is intended for informational purposes only, and no warranty as to its accuracy is provided or implied. The Information was collected from third party sources and is subject to change without notice. Ontario Health (Ontario Renal Network) makes no warranty that the Information is current. The Information is intended for use by healthcare professionals to advise patients of drug funding options that may be available to them. Do not act or rely upon the Information without exercising your independent judgment or seeking the advice of a qualified professional. Anyone using the Information does so at his or her own risk. The drug funding options described on this website are managed and funded by third parties, not by Ontario Health (Ontario Renal Network). Please direct any inquiries to the applicable agency/entity who manages the drug funding option.